Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>MYD88</i> Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia

5 Aug 2015

Abstract excerpt

Patients with Waldenstrom's macroglobulinemia without mutations in MYD88 tend to have a shorter median survival and a lower probability of response to ibrutinib than do those with MYD88 mutations.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Gastrointestinal Tumor Research and Treatment
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26244327
DOI: 10.1056/nejmc1506192

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>MYD88</i> Mutations and Response to Ibrutinib in Waldenström's MacroglobulinemiaPMID 26244327Read ↗

MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.Semantic proximity Read ↗

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Semantic proximity Read ↗

Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.Semantic proximity Read ↗

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

<i>MYD88</i>mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpartSemantic proximity Read ↗

MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.Semantic proximity Read ↗

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.Semantic proximity Read ↗

[New developments in Waldenström's macroglobulinemia].Semantic proximity Read ↗

Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.Semantic proximity Read ↗

A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival.Semantic proximity Read ↗

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.